Stable Cell Line Development & Validation Service

We begin by clarifying the target reporter system, cell model, application goal, and downstream assay requirements.

• Define the reporter or biosensor of interest, such as MitoTimer, mito-Keima-like reporters, mitophagy reporters, mitochondrial Ca²⁺ sensors, ATP/ADP biosensors, NADH/NAD⁺ reporters, redox sensors, pH sensors, membrane potential reporters, or customized mitochondrial fluorescent tools.
• Review the target cell model, including cancer cell lines, iPSC-derived cells, cardiomyocytes, neurons, macrophages, hepatocytes, renal tubular cells, stem cells, organoid-compatible models, or client-provided cell lines.
• Confirm whether the project requires stable pool generation, monoclonal cell line development, inducible expression, reporter knock-in, overexpression, pathway reporter design, or disease mutation-bearing cell models.
• Define downstream platforms, such as confocal imaging, live-cell time-lapse imaging, flow cytometry, fluorescence plate readers, high-content imaging, drug screening, or functional mitochondrial profiling.

Based on project goals, we design an expression strategy that balances reporter performance, biological relevance, and assay reproducibility.

• Select the expression format, including plasmid-based expression, lentiviral expression, transposon-mediated integration, CRISPR knock-in, safe-harbor insertion, inducible expression, or reporter cassette engineering.
• Design reporter constructs with optimized mitochondrial targeting sequences, fluorescent protein tags, biosensor domains, linker regions, selection markers, and promoter systems.
• Select constitutive, tissue-relevant, low-expression, high-expression, or doxycycline-inducible promoter formats according to reporter sensitivity and cell tolerance.
• Design fluorescent channel compatibility for green, red, far-red, dual-channel, ratiometric, or multicolor imaging workflows.
• Plan controls, including empty-vector controls, non-targeting controls, localization controls, positive-response models, and parental cell line references.

After the design strategy is confirmed, we establish the reporter system in the target cells using the most suitable delivery method.

• Optimize transfection, electroporation, nucleofection, or viral transduction conditions according to cell type and viability.
• Generate stable pools through antibiotic selection, fluorescence enrichment, or reporter-positive cell sorting.
• Monitor reporter expression, cell recovery, viability, morphology, and early signal consistency during selection.
• Adjust selection pressure, multiplicity of infection, expression level, and culture conditions to reduce toxicity and improve signal stability.
• Preserve stable pools for early assay testing or proceed to monoclonal cell line development when required.

For applications requiring higher reproducibility, we isolate and expand monoclonal reporter cell lines.

• Perform limiting dilution, single-cell sorting, colony picking, or clone isolation according to cell type and project needs.
• Expand candidate clones under controlled culture conditions.
• Screen clones for reporter expression level, fluorescence intensity, mitochondrial localization, growth behavior, and morphology.
• Identify clones with balanced signal strength, low background, stable expression, and minimal impact on cellular phenotype.
• Establish backup clone banks and parental/stable-pool comparisons for downstream validation.

Stable reporter cell lines are validated to confirm correct reporter presence, stable expression, and reproducible signal behavior.

• Confirm reporter integration or construct presence using PCR-based assays, sequencing, copy-number assessment, or junction validation when applicable.
• Measure reporter expression by fluorescence microscopy, flow cytometry, qPCR, immunoblotting, or plate-reader-based fluorescence detection.
• Evaluate expression stability across passages.
• Assess inducible expression performance, including basal leakage, induction efficiency, induction window, and dose-dependent response when applicable.
• Confirm clonal identity, mycoplasma-free status, and cell growth characteristics according to project requirements.

For mitochondrial reporter models, we validate whether the reporter correctly localizes to mitochondria and responds to relevant biological perturbations.

• Perform co-localization imaging with mitochondrial markers.
• Evaluate mitochondrial network labeling, subcellular background, cytosolic leakage, lysosomal accumulation, or nuclear mislocalization.
• Test reporter response under mitochondrial perturbations, such as uncouplers, oxidative stress, hypoxia/reoxygenation, mitophagy induction, metabolic inhibition, calcium overload, or nutrient stress.
• Compare reporter signal with orthogonal mitochondrial assays, such as membrane potential, ROS, ATP/ADP, NADH/NAD⁺, calcium, pH, mitophagy, apoptosis, or cell viability readouts.
• Establish quantitative metrics such as red/green ratio, ΔF/F₀, mitochondrial/cytosolic ratio, puncta count, colocalization coefficient, dose-response curve, and time-course response.